利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

2 条记录 (耗时 0.016 秒)

    NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A
    2.
    发明公开
    NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A 有权
    NEUARTIGE INHIBITORVERBINDUNGEN DER PHOSPHODIESTERASE TYP 10A

    公开(公告)号：EP2895489A1

    公开(公告)日：2015-07-22

    申请号：EP13765695.5

    申请日：2013-09-16

    申请人： AbbVie Deutschland GmbH & Co. KG ,  AbbVie Inc.

    发明人： GENESTE, Hervé ,  OCHSE, Michael ,  DRESCHER, Karla ,  JAKOB, Clarissa ,  TORRENT, Maricel

    IPC分类号： C07D491/04 ,  C07D495/04 ,  C07D498/04 ,  A61K31/502 ,  A61P25/00

    CPC分类号： C07D471/14 ,  A61K31/4985 ,  C07D491/04 ,  C07D491/14 ,  C07D495/04 ,  C07D495/14 ,  C07D498/04 ,  C07D498/14 ,  C07D513/14

    摘要： The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof. where in formula I the variables X, Y, Q
    1 , Q
    2 have the following meanings: X is C-R
    3 or N; Q
    1 is S or O and Q
    2 is C-R
    4 or N and Q
    2 is connected to X via a double bond while Q
    1 is connected to X via a single bond; or Q
    2 is S or O and Q
    1 is C-R
    4 or N and Q
    1 is connected to X via a double bond while Q
    2 is connected to X via a single bond; Y is C-R
    5 or N; where in formula I the variables R
    1 , R
    2 , R
    3 , R
    4 and R
    5 are as defined in the claims The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

    摘要翻译： 本发明涉及式I化合物，N-氧化物，互变异构体，前药及其药学上可接受的盐。 在式I中，变量X，Y，Q1，Q2具有以下含义：X为C-R3或N; Q1是S或O，Q2是C-R4或N，Q2通过双键连接到X，而Q1通过单键连接到X; 或Q2是S或O，Q1是C-R4或N，并且Q1通过双键连接到X，而Q2通过单键连接到X; Y为C-R5或N; 在式I中，变量R1，R2，R3，R4和R5如权利要求中所定义。式I化合物，N-氧化物，互变异构体，其前药和药学上可接受的盐是磷酸二酯酶10A型和 用于制造药物，因此其适用于治疗或控制选自神经障碍和精神障碍的医学病症，用于改善与此类障碍相关的症状并降低此类疾病的风险。